Camlin Fine Sciences has allotted 10,400 equity shares under ESOP on 15 March 2024. Consequently, the paid up equity share capital has increased to o 167465207 equity shares of face value of Re.1/�] each aggregating to Rs. 16,74,65,207/�]. Powered by Capital Market - Live News

Net loss of Camlin Fine Sciences reported to Rs 11.79 crore in the quarter ended December 2023 as against net profit of Rs 24.04 crore during the previous quarter ended December 2022. Sales declined 0.50% to Rs 385.89 crore in the quarter ended December 2023 as against Rs 387.84 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales385.89387.84 -1 OPM %6.0512.83 - PBDT10.8547.97 -77 PBT-9.7331.79 PL NP-11.7924.04 PL Powered by Capital Market - Live News

Camlin Fine Sciences will hold a meeting of the Board of Directors of the Company on 9 February 2024.Powered by Capital Market - Live News

Net loss of Camlin Fine Sciences reported to Rs 19.38 crore in the quarter ended September 2023 as against net profit of Rs 13.02 crore during the previous quarter ended September 2022. Sales declined 16.01% to Rs 405.88 crore in the quarter ended September 2023 as against Rs 483.25 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales405.88483.25 -16 OPM %6.1911.42 - PBDT7.1239.64 -82 PBT-12.0925.61 PL NP-19.3813.02 PL Powered by Capital Market - Live News

Camlin Fine Sciences announced that the temporarily closure of Diphenol Plant of its wholly owned subsidiary, CFS Europe SPA situated in Ravenna, Italy shall be extended on account of continuing difficult macro�]economic situation in Europe coupled with low pricing and weak demand across the industry. Such closure shall continue until the situation improves for the resumption of the operation of the plant.Powered by Capital Market - Live News